№ files_lp_4_process_3_072373
File format: docx Character count: 13020 File size: 35 KB
Case series of three patients with anaplastic large cell lymphoma showing varied clinical presentations, immunophenotype, and prognosis, emphasizing the role of immunohistochemistry in diagnosis and prognostication.
Note: Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplementary Methods for Flow Cytometry, Immunofluorescence, and Immunohistochemistry in Urothelial Carcinoma Research
Year: Not specified
Region / City: Not specified
Topic: Cancer research, Urothelial carcinoma
Document type: Research methodology
Institution: Not specified
Author: Not specified
Target audience: Researchers in oncology and immunology
Period of validity: Not specified
Approval date: Not specified
Modification date: Not specified
Amendment to MBS item 72814 for programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) testing to include testing for advanced triple negative breast cancer (TNBC) patients
Year: 2023
Region / City: Australia
Subject: Health / Oncology
Document Type: Official Announcement
Organization: Department of Health and Aged Care
Author: Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience: Healthcare providers, specialists
Effective Date: 1 September 2023
Approval Date: 10 August 2023
Changes Date: 1 September 2023
Clinical Category: Pathology Services
Procedure Type: Type C
Private Health Insurance Classification: Support List (pathology)
MBS Item: 72814
PBS Listing: pembrolizumab (Keytruda®)
Eligibility Criteria: Advanced TNBC, PD-L1 Combined Positive Score (CPS) ≥10
Consulted Stakeholders: Clinical experts, providers, consumer health representatives
Review and Monitoring: Compliance audits
More Information: www.mbsonline.gov.au
Description: Official update on the inclusion of PD-L1 immunohistochemistry testing for advanced triple negative breast cancer (TNBC) patients under the Medicare Benefits Schedule (MBS) effective 1 September 2023, aligned with PBS listing for pembrolizumab.
Solicitation and Award of Contract for Immunohistochemistry Reagents and Supplies at Audie L. Murphy VA Hospital, 2018
Year: 2018
Region/City: Amarillo, TX, United States
Subject: Procurement of Immunohistochemistry Reagents and Supplies
Document Type: Government Contract Solicitation and Award
Issuing Agency: Department of Veterans Affairs, Contracting Section
Contractor: Roche (Ventana Industries, Inc.)
Target Audience: Vendors capable of supplying proprietary reagents for Ventana Benchmark instrumentation
Effective Period: Upon award, continuing as required for contract fulfillment
Award/Effective Date: 2018-10-09
Solicitation Number: 436C25719Q0001
Delivery Location: Molecular Laboratory, Pathology & Laboratory Medicine Service, Audie L. Murphy VA Hospital
Payment Terms: Net 30, electronic submission via Tungsten Network
NAICS: 325412
Contract Type: Firm-fixed-price commercial item contract
Method of Solicitation: RFQ/IFB/RFP
Clinical Sample Patient Information of RT-qPCR, Immunohistochemistry Staining (IHC), and Western Blot (WB)
Year: NA
Region / City: NA
Topic: Clinical sample analysis
Document Type: Research Data
Organization / Institution: NA
Author: NA
Target Audience: NA
Period of Validity: NA
Approval Date: NA
Date of Changes: NA
Contextual description: Data presentation of patient samples analyzed by RT-qPCR, immunohistochemistry, and Western blot methods.
Topics: prognostication anaplastic Immunohistochemistry